This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1995 Jul;45(7):1245-7.

doi: 10.1212/wnl.45.7.1245.

Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability

PMID: 7617175
DOI: 10.1212/wnl.45.7.1245

Editorial

Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability

J S Wolinsky. Neurology. 1995 Jul.

. 1995 Jul;45(7):1245-7.

doi: 10.1212/wnl.45.7.1245.

Author

PMID: 7617175
DOI: 10.1212/wnl.45.7.1245

No abstract available

PubMed Disclaimer

Comment in

Editorials in scientific publications.
Feasby TE. Feasby TE. Neurology. 1996 Mar;46(3):883. Neurology. 1996. PMID: 8618717 No abstract available.

Comment on

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Johnson KP, et al. Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268. Neurology. 1995. PMID: 7617181 Clinical Trial.

Similar articles

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Johnson KP, et al. Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701. Neurology. 1998. PMID: 9521260 Clinical Trial.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Johnson KP, et al. Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268. Neurology. 1995. PMID: 7617181 Clinical Trial.
Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).
Johnson KP. Johnson KP. Mult Scler. 1996 Jul;1(6):325-6. doi: 10.1177/135245859600100606. Mult Scler. 1996. PMID: 9345409 Clinical Trial.
Copolymer-1 in the treatment of multiple sclerosis.
Boyden KM. Boyden KM. J Neurosci Nurs. 1998 Apr;30(2):135-9; quiz 140-1. doi: 10.1097/01376517-199804000-00008. J Neurosci Nurs. 1998. PMID: 9642622 Review.
Glatiramer acetate in multiple sclerosis.
Mezzapesa DM, Rovaris M, Filippi M. Mezzapesa DM, et al. Expert Rev Neurother. 2005 Jul;5(4):451-8. doi: 10.1586/14737175.5.4.451. Expert Rev Neurother. 2005. PMID: 16026228 Review.

See all similar articles

Cited by

Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action.
Damal K, Stoker E, Foley JF. Damal K, et al. Biologics. 2013;7:247-58. doi: 10.2147/BTT.S53007. Epub 2013 Nov 27. Biologics. 2013. PMID: 24324326 Free PMC article. Review.
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.
Garg N, Smith TW. Garg N, et al. Brain Behav. 2015 Sep;5(9):e00362. doi: 10.1002/brb3.362. Epub 2015 Aug 3. Brain Behav. 2015. PMID: 26445701 Free PMC article. Review.
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.
Kagitani-Shimono K, Mohri I, Fujitani Y, Suzuki K, Ozono K, Urade Y, Taniike M. Kagitani-Shimono K, et al. J Neuroinflammation. 2005 Apr 6;2(1):10. doi: 10.1186/1742-2094-2-10. J Neuroinflammation. 2005. PMID: 15813970 Free PMC article.
Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel.
Korczyn AD, Nisipeanu P. Korczyn AD, et al. J Neurol. 1996 Apr;243(4 Suppl 1):S23-6. doi: 10.1007/BF00873698. J Neurol. 1996. PMID: 8965117 Clinical Trial.
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.
Hohlfeld R, Wekerle H. Hohlfeld R, et al. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14599-606. doi: 10.1073/pnas.0404874101. Epub 2004 Aug 11. Proc Natl Acad Sci U S A. 2004. PMID: 15306684 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information